S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Accolade Stock Forecast, Price & News

+0.26 (+2.89%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
867,373 shs
Average Volume
1.65 million shs
Market Capitalization
$658.69 million
P/E Ratio
Dividend Yield
Price Target

Accolade MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
81.6% Upside
$16.80 Price Target
Short Interest
7.20% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.15mentions of Accolade in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$37,571 Sold Last Quarter
Proj. Earnings Growth
From ($2.96) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.51 out of 5 stars

Business Services Sector

25th out of 472 stocks

Business Services, Not Elsewhere Classified Industry

12th out of 146 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

Accolade logo

About Accolade (NASDAQ:ACCD) Stock

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

ACCD Stock News Headlines

Accolade Moves Higher But Growth Is Slowing 
Accolade (NASDAQ: ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company’s business and has on track to continue growing but there is a fly in the ointment.
Here's Why Accolade Shares Are Trading Higher Today
Accolade (NASDAQ:ACCD) Stock Price Up 13.9%
Accolade (NASDAQ:ACCD) Shares Up 13.9%
See More Headlines

Industry, Sector and Symbol

Business services, not elsewhere classified
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$310.02 million
Book Value
$7.51 per share


Free Float
Market Cap
$658.69 million
Not Optionable

Accolade Frequently Asked Questions

Should I buy or sell Accolade stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Accolade stock.
View analyst ratings for Accolade
or view top-rated stocks.

What is Accolade's stock price forecast for 2022?

15 brokers have issued 12 month target prices for Accolade's shares. Their ACCD stock forecasts range from $8.00 to $54.00. On average, they anticipate Accolade's share price to reach $16.80 in the next twelve months. This suggests a possible upside of 81.6% from the stock's current price.
View analysts' price targets for Accolade
or view top-rated stocks among Wall Street analysts.

How has Accolade's stock price performed in 2022?

Accolade's stock was trading at $26.36 at the beginning of 2022. Since then, ACCD shares have decreased by 64.9% and is now trading at $9.25.
View the best growth stocks for 2022 here

When is Accolade's next earnings date?

Accolade is scheduled to release its next quarterly earnings announcement on Thursday, October 6th 2022.
View our earnings forecast for Accolade

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) released its earnings results on Thursday, June, 30th. The company reported ($4.92) EPS for the quarter, missing the consensus estimate of ($0.73) by $4.19. The firm had revenue of $85.53 million for the quarter, compared to analysts' expectations of $81.97 million. Accolade had a negative net margin of 124.17% and a negative trailing twelve-month return on equity of 23.63%. The business's revenue for the quarter was up 43.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.52) earnings per share.
View Accolade's earnings history

What guidance has Accolade issued on next quarter's earnings?

Accolade issued an update on its second quarter 2023 earnings guidance on Thursday, July, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $82.00 million-$83.50 million, compared to the consensus revenue estimate of $84.05 million.

Who are Accolade's key executives?

Accolade's management team includes the following people:
  • Mr. Rajeev Singh, Chairman & CEO (Age 53, Pay $828k)
  • Mr. Robert Cavanaugh, Pres (Age 53, Pay $706.12k)
  • Mr. Stephen H. Barnes CPA, CFO & Treasurer (Age 50, Pay $610.6k)
  • Mr. Phong Nguyen, Chief Operating Officer
  • Mr. Harish Naidu, Chief Technology Officer
  • Mr. Todd Friedman, Sr. VP of Investor Relations
  • Mr. Richard Eskew, Exec. VP, Gen. Counsel, Chief Privacy Officer & Sec.
  • Mr. William S. Morrison, Sr. VP of Strategy & Corp. Devel.
  • Ms. Carolina Lobo, Chief Marketing Officer
  • Ms. Jennifer Hanson, Exec. VP of People and Culture & Chief HR Officer

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade CEO Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among Accolade's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include (HON), CVS Health (CVS), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

(ACCD) raised $176 million in an initial public offering on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

What is Accolade's stock symbol?

Accolade trades on the NASDAQ under the ticker symbol "ACCD."

How do I buy shares of Accolade?

Shares of ACCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accolade's stock price today?

One share of ACCD stock can currently be purchased for approximately $9.25.

How much money does Accolade make?

Accolade (NASDAQ:ACCD) has a market capitalization of $658.69 million and generates $310.02 million in revenue each year. The company earns $-123,120,000.00 in net income (profit) each year or ($6.09) on an earnings per share basis.

How many employees does Accolade have?

Accolade employs 2,350 workers across the globe.

How can I contact Accolade?

Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for Accolade is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com.

This page (NASDAQ:ACCD) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.